IP Library › Granted Patent US 9,725,511
Granted Patent B2
US 9,725,511 · App. 14/073,137 · Granted Aug 8, 2017

Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4

Inventors: Birgit Bossenmaier (Seefeld, DE); Guy Georges (Habach, DE); Michael Gerg (Munich, DE); Gerhard Niederfellner (Oberhausen, DE); Christian Scholz (Penzberg, DE); Michael Schraeml (Penzberg, DE)
Assignee: Hoffmann-La Roche Inc.
C07K16/2863A61K47/48484A61K47/48569C07K16/32A61K2039/505C07K2317/24C07K2317/33C07K2317/34C07K2317/55C07K2317/73C07K2317/75C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,725,511
App. No.
14/073,137
Granted
Aug 8, 2017
Kind
B2
Abstract

The invention relates to anti-HER3/HER4 antigen binding proteins, e.g. anti-HER3/HER4 antibodies, that bind to the beta-hairpin of HER3 and the beta-hairpin of HER4, methods for selecting these antigen binding proteins, their preparation and use as medicament.

Claims (77)

1. An isolated antibody that binds to human HER3 and binds to human HER4, wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

2. An isolated antibody that binds to human HER3 and binds to human HER4, wherein the antibody comprises

i) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; or

ii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; or

iii) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; or

iv) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

3. An antibody comprising:

a) a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:36; or

b) a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:37; or

c) a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:36; or

d) a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:37; or

e) a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:36; or

f) a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:37.

4. The antibody of claim 1 or claim 2 , which is a full length IgG1 antibody or IgG4 antibody.

5. The antibody of claim 1 or claim 2 , which is a Fab fragment.

6. An immunoconjugate comprising the antibody of claim 1 or claim 2 and a cytotoxic agent.

7. A pharmaceutical formulation comprising the antibody of claim 1 or claim 2 and a pharmaceutically acceptable carrier.

8. The antibody of claim 2 , wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41; and

f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

9. The antibody of claim 2 , wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:38;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

10. The antibody of claim 2 , wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:41; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

11. The antibody of claim 2 , wherein the antibody comprises

(a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25;

(b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:39;

(c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27;

(d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:40;

(e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:42; and

(f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

12. The antibody of claim 3 , wherein the antibody comprises a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:36.

13. The antibody of claim 3 , wherein the antibody comprises a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:37.

14. The antibody of claim 3 , wherein the antibody comprises a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:36.

15. The antibody of claim 3 , wherein the antibody comprises a d) a VH sequence of SEQ ID NO:34 and a VL sequence of SEQ ID NO:37.

16. The antibody of claim 3 , wherein the antibody comprises a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:36.

17. The antibody of claim 3 , wherein the antibody comprises a VH sequence of SEQ ID NO:35 and a VL sequence of SEQ ID NO:37.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: BOSSENMAIER, BIRGIT; GEORGES, GUY; GERG, MICHAEL; NIEDERFELLNER, GERHARD; SCHOLZ, CHRISTIAN; SCHRAEML, MICHAEL
To: ROCHE DIAGNOSTICS GMBH
Reel/Frame 036849/0235 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: ROCHE DIAGNOSTICS GMBH
To: F. HOFFMANN-LA ROCHE AG
Reel/Frame 036849/0398 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2015
From: F. HOFFMANN-LA ROCHE AG
To: HOFFMANN-LA ROCHE INC.
Reel/Frame 036849/0604 →
Priority Claims (1)
EP 12191871 · Nov 8, 2012 · regional
Continuity (1)
Related Publication 20140186354A1 · Jul 3, 2014